Access Denied
IMPORTANT! If you’re a store owner, please make sure you have Customer accounts enabled in your Store Admin, as you have customer based locks set up with EasyLockdown app. Enable Customer Accounts
Minor Cannabinoids — CBG, CBN, THCV
Where They Came From, Where They Are, Where They’re Going
-
By Jeremy Amos
Published: Friday, Oct 3, 2025
Yesterday: Hidden in the Shadows
For decades, cannabis research focused almost exclusively on THC and CBD. Minor cannabinoids like CBG (cannabigerol), CBN (cannabinol), and THCV (tetrahydrocannabivarin) were present in small amounts and harder to extract.
- CBG: Known as the “mother cannabinoid,” since it’s a precursor to many others. Historically ignored, but incredibly effective.
- CBN: An oxidation byproduct of THC, associated with sleep in folklore, but rarely studied.
- THCV: Found in trace amounts, with unique psychoactive effects at high doses.
Takeaway: Yesterday, minor cannabinoids were scientifically intriguing but commercially impractical.
Title
Today: Market Momentum
Extraction innovation and consumer curiosity have changed the game.
- CBG: Marketed for focus, energy, and gut health. Increasingly available thanks to genetics that boost CBG content.
- CBN: Popular in sleep formulations (often paired with CBD + melatonin). Demand rising as consumers seek alternatives to traditional sleep aids.
- THCV: Generating buzz for appetite regulation and potential metabolic benefits—though clinical data is limited.
Market reality:
- Minor cannabinoids are still a small slice of the pie, but seeing increased growth as consumers search for targeted wellness.
- Pricing remains higher than CBD, though it’s dropping as supply chains improve.
- Regulatory status varies, with some minor cannabinoids lumped into “novel food” categories in Europe or facing scrutiny elsewhere.
Takeaway: Today, minor cannabinoids are the “next frontier” - capturing attention, but still in early days.
Title
Tomorrow: Precision + Proof
The future of minor cannabinoids lies in science and specificity.
- CBG: Ongoing studies into gut health, inflammation, and focus. May emerge as a mainstream wellness cannabinoid.
- CBN: Deeper clinical trials on sleep and circadian rhythm support. Could become a staple in natural sleep products.
- THCV: If research validates metabolic and appetite effects, it could become one of the most disruptive cannabinoids.
- Blended formulations: Expect multi-cannabinoid products targeting specific outcomes (e.g., “Sleep blend: CBD + CBN + botanicals”).
Takeaway: Tomorrow, the winners will be the brands that align minor cannabinoids with real evidence and deliver them in formats consumers trust.
Title
What This Means for Brands (and OBX)
- Educate. Consumers are curious but often misinformed—clear, evidence-based messaging is key.
- Formulate smart. Blend minor cannabinoids where early science is strongest.
- Invest in supply chains. As demand grows, stable and compliant sourcing will be critical.
At OBX, we’re committed to developing minor cannabinoid formulations that are scalable, evidence-based, and transparent—helping partners get ahead of the curve.
Invalid password
Enter
